Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AEON Biopharma (AEON)
NYSE MKT:AEON
Holding AEON?
Track your performance easily
AEON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.67 - $17.17
Previous Close$0.67
Volume88.04K
Average Volume (3M)1.73M
Market Cap
$26.48M
Enterprise Value$30.01M
Total Cash (Recent Filing)$1.56M
Total Debt (Recent Filing)$5.09M
Price to Earnings (P/E)1.3
Beta0.73
Next Earnings
Aug 12, 2024EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.52
Shares Outstanding39,522,238
10 Day Avg. Volume90,442
30 Day Avg. Volume1,730,846
Standard Deviation0.24
R-Squared0.00485
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-0.14
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda2.82
Forecast
1Y Price Target
$5.00Price Target Upside647.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
AEON Biopharma News
PremiumCompany Announcements
AEON Biopharma Releases New Corporate Presentation
PremiumMarket News
3 Penny Stocks to Watch Now, 7/18/24
Bulls Say, Bears Say
Bulls Say
Biosimilar PathwayA biosimilar pathway potentially provides ABP-450 with a fast and low-cost approach to launch in multiple indications.
Clinical DevelopmentABP-450 is ready to enter Phase 3 in cervical dystonia (CD), which is viewed as a 'low-risk' program since it is one in which neuromodulators have performed very consistently in clinical studies over the years.
R&D ExpensesR&D expenses declined 50.8% YoY to $4.4M from $9.0M in the same period last year and were below the estimate of $5.2M.
Bears Say
Capital RequirementsAeon needs to raise capital, which will likely be dilutive.
CompetitionAeon is competing against entrenched players, most notably Abbvie, with greater resources.
Price TargetGiven the uncertainty in funding, the price target is adjusted to $5 from $6.
---
Ownership Overview
44.15% Insiders
2.33% Mutual Funds
22.20% Other Institutional Investors
31.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AEON FAQ
What was AEON Biopharma’s price range in the past 12 months?
AEON Biopharma lowest stock price was $0.67 and its highest was $17.17 in the past 12 months.
What is AEON Biopharma’s market cap?
Currently, no data Available
When is AEON Biopharma’s upcoming earnings report date?
AEON Biopharma’s upcoming earnings report date is Aug 12, 2024 which is 39 days ago.
How were AEON Biopharma’s earnings last quarter?
AEON Biopharma released its earnings results on Mar 29, 2024. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.4 by -$0.31.
Is AEON Biopharma overvalued?
According to Wall Street analysts AEON Biopharma’s price is currently Undervalued.
Does AEON Biopharma pay dividends?
AEON Biopharma does not currently pay dividends.
What is AEON Biopharma’s EPS estimate?
AEON Biopharma’s EPS estimate is -$0.19.
How many shares outstanding does AEON Biopharma have?
AEON Biopharma has 39,522,240 shares outstanding.
What happened to AEON Biopharma’s price movement after its last earnings report?
AEON Biopharma reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.4. Following the earnings report the stock price went down -1%.
Which hedge fund is a major shareholder of AEON Biopharma?
Among the largest hedge funds holding AEON Biopharma’s share is Saba Capital Management. It holds AEON Biopharma’s shares valued at N/A.
---
AEON Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (647.38% Upside)
$5.00 (647.38% Upside)
Hedge Fund Trend
Decreased
By 636.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 7.2%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-89.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-73.68%
Trailing 12-Months
Company Description
AEON Biopharma
Priveterra Acquisition Corp is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses.
---
AEON Stock 12 Month Forecast
Average Price Target
$5.00
▲(647.38% Upside)
Technical Analysis
Best Analysts Covering AEON
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-63.63%
assigned a buy rating last month
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -63.63% per trade.
---